In the past few years, several studies have demonstrated the potential uses of an imaging biomarker that evaluates in vivo tau retention, which represents a promising, useful biomarker not only for AD but also for other forms of dementia that presents tauopathies, including FTD [41]. The gene discussed is MAPT; the disease is frontotemporal dementia.